Long-term Follow-up Study of BRL-101 for TDT
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Provision of written informed consent for this study by subjects, or as applicab... [+1]
Review clinical trials related to Thalassemia, Beta. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Provision of written informed consent for this study by subjects, or as applicab... [+1]
Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how participants' body responds to the fludarabine and dexamethasone, the study doctor may decide participants should receive another drug, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of participants' routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.
Age ≥ 2 and ≤ 50 years [+23]
Prior myeloablative allogeneic HCT. [+9]
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disea... [+2]
Patients treated with stem cell transplantation or genetic therapy. [+2]
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Provision of written informed consent for this study by subjects, or as applicab... [+1]
This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.
Age 3-35 years old (inclusive), male or female; [+7]
Diagnosis of associated α-thalassemia: > 1 alpha chain deletion or alpha gene fu... [+14]